Emerging Therapeutic Targets and Drug Delivery Approaches in IBD, Volume 101 in this ongoing series, highlights new advances, with this volume presenting interesting chapters on timely topics, including Fibrosis in IBD – AXL as a Promising Therapeutic Target, Developing a pathway to test anti-fibrotic drugs in Crohn’s disease, Emerging therapeutics for the management of intestinal fibrosis and strictures, GCPII for IBD, Fistulas/stem cell products for IBD/Crohn’s, The landscape of new therapeutic opportunities for IBD, TL1A : A Model For The Use Of Precision Medicine For The Treatment of Crohn’s Disease and Ulcerative Colitis, Dectin-1 as a therapeutic target for IBD, and more.
Additional sections cover BRD4 as an Emerging Epigenetic Therapeutic Target for Inflammatory Bowel Diseases, Scripps - S1P, The potential of targeting TREM-1 in Inflammatory Bowel Disease, and Microbiome therapies.
1. 1 Introduction: unmet therapeutic needs in IBD - p. 1 2. 2 Restoration of immune homeostasis - p. 6 3. 3 Restoration of barrier function and promotion of mucosal healing for prevention of disease progression - p. 21 4. 4 Reversing and preventing disease complications - p. 28 5. 5 Restoration of microbial homeostasis for disease management - p. 38 6. 6 Targeted drug delivery systems for enhanced therapeutic efficacy with minimal side effects - p. 45 7. 7 Precision medicine for personalized interventions - p. 48 8. 8 Path forward toward personalized and holistic care - p. 52 9. Conflict of interest statement - p. 53 10. References - p. 81 11. Chapter Two: Anti-fibrotics in inflammatory bowel diseases: Challenges and successes - p. 85 12. Chapter Three: Emerging therapeutics for the management of intestinal fibrosis and strictures - p. 107 13. Chapter Four: AXL: A novel therapeutic target in IBD - p. 141 14. Chapter Five: Current and emerging therapeutic strategies for perianal fistula in Crohn’s disease patients - p. 157 15. Chapter Six: The discovery and development of the sphingosine 1-phosphate receptor modulator ozanimod in ulcerative colitis - p. 183 16. Chapter Seven: BRD4 as an emerging epigenetic therapeutic target for inflammatory bowel disease - p. 203 17. Chapter Eight: Dectin-1 as a therapeutic target for inflammatory bowel disease - p. 237 18. Chapter Nine: Targeting glutamate carboxypeptidase II in IBD - p. 264 19. Chapter Ten: TL1A: A model for a precision medicine approach in the treatment of Crohn’s disease and ulcerative colitis - p. 287 20. Chapter Eleven: The potential of targeting TREM-1 in IBD - p. 301
Emerging Therapeutic Targets and Drug Delivery Approaches in IBD, Volume 101 in this ongoing series, highlights new advances, with this volume presenting interesting chapters on timely topics, including Fibrosis in IBD – AXL as a Promising Therapeutic Target, Developing a pathway to test anti-fibrotic drugs in Crohn’s disease, Emerging therapeutics for the management of intestinal fibrosis and strictures, GCPII for IBD, Fistulas/stem cell products for IBD/Crohn’s, The landscape of new therapeutic opportunities for IBD, TL1A : A Model For The Use Of Precision Medicine For The Treatment of Crohn’s Disease and Ulcerative Colitis, Dectin-1 as a therapeutic target for IBD, and more.
Additional sections cover BRD4 as an Emerging Epigenetic Therapeutic Target for Inflammatory Bowel Diseases, Scripps - S1P, The potential of targeting TREM-1 in Inflammatory Bowel Disease, and Microbiome therapies.
1. 1 Introduction: unmet therapeutic needs in IBD - p. 1 2. 2 Restoration of immune homeostasis - p. 6 3. 3 Restoration of barrier function and promotion of mucosal healing for prevention of disease progression - p. 21 4. 4 Reversing and preventing disease complications - p. 28 5. 5 Restoration of microbial homeostasis for disease management - p. 38 6. 6 Targeted drug delivery systems for enhanced therapeutic efficacy with minimal side effects - p. 45 7. 7 Precision medicine for personalized interventions - p. 48 8. 8 Path forward toward personalized and holistic care - p. 52 9. Conflict of interest statement - p. 53 10. References - p. 81 11. Chapter Two: Anti-fibrotics in inflammatory bowel diseases: Challenges and successes - p. 85 12. Chapter Three: Emerging therapeutics for the management of intestinal fibrosis and strictures - p. 107 13. Chapter Four: AXL: A novel therapeutic target in IBD - p. 141 14. Chapter Five: Current and emerging therapeutic strategies for perianal fistula in Crohn’s disease patients - p. 157 15. Chapter Six: The discovery and development of the sphingosine 1-phosphate receptor modulator ozanimod in ulcerative colitis - p. 183 16. Chapter Seven: BRD4 as an emerging epigenetic therapeutic target for inflammatory bowel disease - p. 203 17. Chapter Eight: Dectin-1 as a therapeutic target for inflammatory bowel disease - p. 237 18. Chapter Nine: Targeting glutamate carboxypeptidase II in IBD - p. 264 19. Chapter Ten: TL1A: A model for a precision medicine approach in the treatment of Crohn’s disease and ulcerative colitis - p. 287 20. Chapter Eleven: The potential of targeting TREM-1 in IBD - p. 301
